Welcome to BioSeeker Group!

Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 7056
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies.

    To find out more about Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
10 Disclaimer 1724
Figures: Includes 8 Figures
Tables: Includes 309 Tables
Total Number of Pages: 1,755

Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
AB Science
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
ACT Biotech
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanomics
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
AGY Therapeutics
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allist Pharmaceuticals
Allos Therapeutics
Allostera
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
ALSP
Altor BioScience
Ambit Biosciences
Amgen
Amorfix Life Sciences
Amphora
AngioChem
Ansaris
Antisoma
Aphios
Apogee Biotechnology
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascend Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Beta Pharma
Betagenon
Bio-Path Holdings
BioAxone
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
BioMarin
Bionovo
BioSante
Biosceptre
Biotecnol
Biotest
Biotica Technology
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Innovations
Cancer Research Technology
Catalyst Biosciences
Cel-Sci
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CerRx
CG Therapeutics
Chemokine Therapeutics
Chiesi
Chong Kun Dang
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
CSL
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Domainex
Dompe
Dong-A
Dongkook Pharm
Douglas
Dr Reddy’s
Dyax
ECI
Eisai
Elan
Elara Pharmaceuticals
ElexoPharm
Eli Lilly
Emergent BioSolutions
Endoceutics
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Ergon Pharmaceuticals
Erimos
Esperance Pharmaceuticals
Etubics
Eucodis
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Formula Pharmaceuticals
Fresenius
Fusion Antibodies
Galapagos
Galaxy Biotech
Galectin Therapeutics
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
GlyTag
Got-a-Gene
GPC Biotech
Gradalis
Green Cross
Hanmi
Harbor BioSciences
Hawthorn Pharmaceuticals
Heidelberg Pharma
Hoffmann-La Roche
Hospira
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incozen Therapeutics
Incyte Corporation
Inex
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intarcia Therapeutics
Intellikine
Intezyne Technologies
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
Kaketsuken
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
KuDOS
Kyowa Hakko Kirin
Kyto Biopharma
Leo
Lexicon Pharmaceuticals
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
MAT Biopharma
MaxoCore Pharmaceuticals
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
MetaMol Theranostics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
Mologen
Mycenax
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nerviano Medical Sciences
Neuren
Neurocrine Biosciences
NexGenix Pharmaceuticals
NexusPharma
NicOx
Nidus Laboratories
NIH
Nimbus Discovery
Nippon Kayaku
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
NovaLead
Novartis
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
Oncolix
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Pacific Biotech
Paladin Labs
Panacea
PanaGin
PanGenetics
Pantarhei Bioscience
Pathway Therapeutics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Prima Biomed
Proacta
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProStrakan
Provid
PTC Therapeutics
QLT
Quantum Pharmaceuticals
R&R
Radient Pharmaceuticals
Ramot
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Samtheo Biopharma
Samyang
Sanofi
Santaris Pharma
Sareum
Savient Pharmaceuticals
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
SEEK
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Shanghai CP Guojian
Shenogen
Sigma-Tau
Silence Therapeutics
Sirnaomics
SRI International
Stainwei Biotech
Sun Pharma Advanced Research
Sunesis
Sunol Molecular
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Taiwan Liposome Company
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
Taxolog
TCD Pharma
TeGenero
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxon Biotech
Velacor Therapeutics
Verastem
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
ViroMed
ViroTarg
Viventia Biotech
Wyeth
XBiotech
Xcovery
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
177-Lu-AMBA
17ß-hydroxysteroid dehydrogenase-1 inhibitors
2-methoxyestradiol
2aG4-IL-2 fus protein + PS MAb
4-hydroxytamoxifen
5-FU
852A
9-aminocamptothecin
AB-16B5
abagovomab
abiraterone acetate
ABT-510
AC-480
ACC inhibitor
acolbifene
adecatumumab
aderbasib
Adva-27a
AE-37
AEE-788
AEG-35156
AEZS-108
AF-802
afatinib
aflibercept
AFM-21
AG-1
agatolimod
aglycon protopanaxadiol
AGS-1C4D4
ALD-518
alemtuzumab
alvespimycin hydrochloride
alvocidib
amatuximab
AME-133
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
amuvatinib
anastrozole
androgen receptor antagonist
angiopep+paclitaxel
Angiozyme
annamycin
anti-C35 MAb
anti-HER-2/neu antisense
anti-HER2 MAb
anti-HER2neu scFv
anti-Hsp90-alpha MAbs
anti-PCDGF MAbs
anticancers
antiestrogen
apatinib
apricoxib
AR-002
AR-004
AR-42
AR-7BD-33-11A
ARC-100
ARQ-197
ARQ-621
ARRY-380
arzoxifene hydrochloride
AS-1402
ASP-08126
AT-7519
AT-9283
atamestane
ATN-224
atrasentan
Auto TAG vaccine
AUY-922
AV-299
AVE-1642
AVI-4126
avorelin
AVX-701
axitinib
AZD-1480
AZD-4547
AZD-4877
AZD-4992
AZD-8055
AZD-8931
bafetinib
BAL-27862
banoxantrone
barasertib
bardoxolone methyl
becatecarin
belimumab
belinostat
bevacizumab
BEZ-235
BGT-226
BHQ880
BI-811283
BIBF-1120
BIW-8556
blinatumomab
BMN-673
BMS-599626
BMS-663513
BMS-690514
BMS-753493
BMS-754807
BMS-777607
BMS-936558
BN-107
bortezomib
bosutinib
brca2
breast cancer therapy
breast cancer vaccine
BreMel/TNF-alpha
brentuximab vedotin
BrevaRex MAb
brivanib alaninate
brivudine
BT-062
BZL-101
CAB-051
Cabozantinib
CAL-101
cancer therapy (1)
cancer therapy (2)
canertinib dihydrochloride
canfosfamide hydrochloride
capecitabine
carbetocin
carlumab
catumaxomab
CBP-501
CC-223
CDX-1307
CDX-1401
CEA cancer vaccine
cediranib
celecoxib
cetuximab
CGX-0682
CH-4986399
CHF-4227
cilengitide
cixutumumab
clofarabine
CMAB302
CMAB304
CNF-2024
conatumumab
contusugene ladenovec
CP-724714
crizotinib
crolibulin
CT-011
CTCE-9908
CTP-37
CUDC-101
custirsen
CVac
CX-4945
CYN-101
D-3263
dabigatran etexilate
dacomitinib
dalotuzumab
danusertib
daratumumab
dasatinib
daunorubicin
denosumab
Diflomotecan
dinaciclib
docetaxel (1)
docetaxel (2)
docetaxel (3)
docetaxel (4)
docetaxel (5)
docetaxel MAb
dovitinib lactate
doxifluridine
doxorubicin (1)
doxorubicin (10)
doxorubicin (11)
doxorubicin (2)
doxorubicin (3)
doxorubicin (4)
doxorubicin (5)
doxorubicin (6)
doxorubicin (7)
doxorubicin (8)
doxorubicin (9)
doxorubicin citrate
DXL-702
E-75
E39
ECI-301
elomotecan
elotuzumab
elsamitrucin
EMD-273063
EMD525797
emepepimut-S
endostatin
endoxifen
eniluracil
ENMD-2076
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
epothilone D
epratuzumab
epratuzumab-Y90
erlotinib
ERR antagonists
ertumaxomab
estetrol
estrogen inhibitors
everolimus
exatecan mesylate
exemestane
Exherin
exisulind
EZH2
F16-IL2
fadrozole
farletuzumab
FASN inhibitors
figitumumab
flt-4 kinase inhibitors
foretinib
formestane (1)
formestane (2)
fosfluridine tidoxil
fostamatinib disodium
FPI-01
fresolimumab
fulvestrant
fusion toxins
Galactomycin-UCLT
galarubicin hydrochloride
galiximab
ganitumab
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
gimatecan
girentuximab
glembatumumab vedotin
GlyB4
golnerminogene pradenovec
goserelin
goserelin acetate ER
GPR40 antagonists
GS-6634
GSK-1059615
GSK-2118436
GSK-2130579A
GSK-2302024A
GVAX
HAS2 inhibitor
HE-3235
Her-2/Neu peptides
HER2 vaccine
her2/neu antigen
Her2/neu gene therapy
huBrE-3 tiuxetan
HuMax-Her2
HuMax-VEGF
I-131-labetuzumab
ibritumomab tiuxetan
IC-83
icotinib hydrochloride
icrucumab
idronoxil
IGF-1 receptor inhibitor
IGN-101
IKKe/TBK1 inhibitor
imatinib mesilate
imetelstat
IMGN-388
immunogene therapy
IMO-2055
IMP-321
Imuteran
INCB-028060
indisulam
ING-1
ingenol mebutate
INGN-225
INGN-241
inherbins
iniparib
INNO-206
inotuzumab ozogamicin
INSM-18
interferon (ß1a)
interleukins
intetumumab
IPH-2102
IPH-3102
ipilimumab
IPP-204106
iratumumab
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
JI-101
JMR-132
KD032
KW-2170
KX2-391
L19-TNFalpha
labetuzumab
labetuzumab-SN-38
lapatinib ditosylate
lapuleucel-T
larotaxel
lasofoxifene
lenvatinib
leptin antagonists
lestaurtinib
letrozole
leucine-doxorubicin
leuprorelin
linifanib
linsitinib
lintuzumab
LIP-131I
LipoVIL12
lonafarnib
lonaprisan
LOR-2040
lorvotuzumab mertansine
Lovaxin B
lucatumumab
lumiliximab
LY-2090314
LY-2157299
LY2495655
lymphomun
MABp1
MAGH-22
mapatumumab
masitinib
MCS-110
MDX-1140
ME-103
MEDI-547
MEDI-551
MEDI-573
Mesd-based peptides
MetXia
MGCD-265
MGN-1601
MGN-1703
midostaurin
milataxel
milatuzumab
milatuzumab-doxorubicin
mitoxantrone
MK-1775
MK-2206
MKC-1
MLN-8237
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
motexafin gadolinium
moxetumomab pasudotox
MP-529
MS-209
MT-110
MUC-1 vaccine
MVA-BN Her-2 vaccine
Nab-docetaxel
naptumomab estafenatox
natalizumab
necitumumab
neratinib
nilotinib
nimotuzumab
NK-012
NL-0031
nolatrexed dihydrochloride
NPB-001-056
NXD-30001
OB-cadherin antibodies
obinutuzumab
oblimersen sodium
OCM-111
OCM-8054
OCM-8224
ofatumumab
OGX-225
OGX-427
olaparib
olaratumab
ON-01910
ON-045270
onartuzumab
Onco-L TCS
oncolytic viruses
Onyvax-105
oregovomab
OSI-027
OSI-7904L
osteolytic disease therapy
Osteopontin-c inhibitor


OTS-102
P276-00
paclitaxel (1)
paclitaxel (10)
paclitaxel (11)
paclitaxel (12)
paclitaxel (13)
paclitaxel (14)
paclitaxel (2)
paclitaxel (3)
paclitaxel (4)
paclitaxel (5)
paclitaxel (6)
paclitaxel (7)
paclitaxel (8)
paclitaxel (9)
paclitaxel polyglumex
paclitaxel-DHA
panitumumab
PankoPep
panobinostat
PANVAC-VF
PAT-SC1
patupilone
pazopanib hydrochloride
PD-0325901
PD-0332991
pegdinetanib
pelitinib
pemetrexed disodium
pentamidine isethionate
peptidomimetics
perifosine
pertuzumab
PF-4856884
PHA-848125AC
PhG-alpha-1
pixantrone
PKI-179
PKI-587
plitidepsin
ponatinib
pralatrexate
Prolanta
Prolanta ER
prostate cancer therapy
PRX-321
PSK-3668
PTC-299
PX-104.1
PX-866
quinacrine
quizartinib dihydrochloride
R-763
radiotherapeutic
RAF-265
raloxifene hydrochloride
ramucirumab
Reditux
regorafenib
retaspimycin
Reximmune-C
Rexin-G
RG-1507
RG-7160
RG-7321
rhErbB3-f
ridaforolimus
rilotumumab
rinfabate
rituximab
robatumumab
romidepsin
romiplostim
RR-310
rubitecan
ruxolitinib
RX-0201-N
S1P3 inhibitor
sabarubicin
sagopilone
samalizumab
SAR-3419
SAR-566658
saracatinib
SBC-202
Sch-57050
SCH-900776
SEL-24-1
seliciclib
selumetinib
semaxanib
seocalcitol
SERM + toxin
SF-1126
siltuximab
simotaxel
sipuleucel-T
siRNA gp96 therapy
sirolimus
SM3
SN-38 (1)
SN-38 (2)
SNG-163
SNG-8023
SNG-8038
sorafenib tosylate
sotatercept
SPC-2968
SR-13668
SR-16157
SR-31747
ß-lapachone
STA-9090
steroid sulfatase inhibitor
STP-503
SU-14813
SU-6668
sunitinib malate
survivin-2B
Sym-004
Symadex
talmapimod
talminogene laherparepvec
tamoxifen (1)
tamoxifen (2)
tamoxifen, oral liquid
tandutinib
tanespimycin
tariquidar
TAS-108
tegafur + uracil
telatinib
telomerase vaccine
temsirolimus
Tenarad
terameprocol
TG-4010
thiocoraline
thymectacin
tigatuzumab
tipifarnib
tivozanib
TLK-58130
TLN-4601
TNF + paclitaxel
TNF-alpha
tocilizumab
toremifene citrate
trastuzumab (1)
trastuzumab (2)
trastuzumab (3)
trastuzumab emtansine
trastuzumab-MMAE conjugate
TRC-105
tremelimumab
triapine
triciribine phosphate
trilostane
triptorelin pamoate
TroVax
TRU-016
TS-1
TTL-2019
TTL-3101
tucotuzumab celmoleukin
U3-1287
Ublituximab
UCN-01
V-930
V935
vandetanib
varlitinib
vatalanib
veliparib
veltuzumab
vemurafenib
vismodegib
VM-206
volasertib
volociximab
vosaroxin
VS-4718
VS-507
VS-5095
VX-001
WX-671
WX-UK1
XL-147
XL-281
XL-413
XL-647
XL-765
Y-90-labetuzumab
YM-155
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab
Zemab
zibotentan
ZYC-300

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies.
    To find out more about Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Complete Target Atlas in Oncology Drug Development: From Tumor to Targeted Therapy
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. Learn More


Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 182 companies plus partners who are today developing 255 Fc epsilon RI signaling pathway targeting drugs in 966 developmental projects in cancer across 148 different targets. In addition, there are 2 suspended drugs and another 84 drugs where development has been ceased. Learn More